Close
Insilico Medicine, led by Alex Zhavoronkov PhD, is participating in various events in Singapore to share insights on AI-powered drug discovery. The company is attending the SCRI Clinical Trials Symposium 2024 and Brainstorm AI 2024 to engage with global leaders in technology and healthcare industries. Alex Zhavoronkov PhD will be speaking on methodologies and considerations for trials involving AI-driven technologies.
The session moderated by Associate Professor Liu Nan will explore critical aspects of conducting trials for AI technologies. Insilico Medicine, founded in 2014, is a pioneer in using generative AI for drug discovery and development. The company has raised over $300 million in funding and has a comprehensive portfolio of assets in drug development.
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
